Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan's $1bn last-minute ticket for Breo Ellipta bandwagon

This article was originally published in Scrip

Executive Summary

Elan has announced a $1 billion payment to Theravance in return for a 21% share of the royalty stream from sales of Breo Ellipta, the once-a-day treatment for chronic obstructive pulmonary disease that was approved by the US FDA on Friday. The one-off cash payment also buys it an interest in three other respiratory products that are yet to be approved.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel